| ￥5800 | |
| Z04371-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | IL-18BP[Biotin],His, Cynomolgus, His tag captured on CM5 Chip via antihis antibody can bind Human IL18, No Tag in SPR assay (Biacore T200). Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 21.14 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. |
| Synonyms | IL-18BP; Igifbp; Interleukin-18-binding protein |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
